Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 7, 2016; 22(37): 8414-8434
Published online Oct 7, 2016. doi: 10.3748/wjg.v22.i37.8414
Published online Oct 7, 2016. doi: 10.3748/wjg.v22.i37.8414
Table 9 Characteristics of studies reporting on poor response based upon magnetic resonance imaging
| Ref. | Year | Chemotherapy protocol | Radiotherapy protocol (Gy) | Surgical procedures | TME | Time to surgery (wk) | Cancer stage Pre neo-adjuvant therapy | Adjuvant therapy |
| Shihab et al[52] | 2011 | APR/AR | Y | |||||
| Patel et al[7] and Siddiqui et al[8] | 2011 and 2012 | APR/AR | Y | |||||
| Patel et al[6] | 2012 | APR/AR | Y | T1/2/3/4, N0/1/2 | Y | |||
| Yu[53] | 2014 (unpublished data from our centre) | Capecitabine, oxaliplatin ± cetuximab | 50.4-54 | Y | T2/3/4 | Y | ||
| Yu[53] | 2014 (unpublished data from our centre) | Capecitabine, oxaliplatin ± cetuximab | 50.4-54 | Y | T2/3/4 | Y |
- Citation: Siddiqui MRS, Bhoday J, Battersby NJ, Chand M, West NP, Abulafi AM, Tekkis PP, Brown G. Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. World J Gastroenterol 2016; 22(37): 8414-8434
- URL: https://www.wjgnet.com/1007-9327/full/v22/i37/8414.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i37.8414